I can add the link here...just search for it. This is the main part of the article. Plus the doctor says he is cautiously optimistic.
This drug seems to improve electrical markers by four times more than the current standard of care drug, which is a medication called donepezil (Aricept),” Prof Macfarlane said.
The result, which came after 36 days of therapy, is already higher than what donepezil reaches after six months of taking it continuously.
“We’ve also had patients and their carers reporting improvements in their thinking, increased alertness and improvement in their organisation and independence,” Prof Macfarlane said.
Patients and carers were so impressed with the changes that they are now trying to double the period of time they can access the drug.
BTW, he is going to Barcelona to present complete 2A results.
why would he fly doctor from Austrialia to Barcelona to present the results ? All this means results for 2A part A and B will be really good. Read between the leaves.
we are doing the reverse..we are moving up because fundamentals are getting much better....
why bother ? He is doing it because he knows its going to be GREAT. And funds only buy stocks over $5, and not on pink OTC. He is preparing for the future. He says it himself - uplisting is for sharing into the future success.
market cap 1.3 billion...buy AVXL for 3x current market cap.
if IBB continues to rise, so will AVXL..if IBB pulls back, AVXL may a bit too. But end of week it will be higher than 1.60. Getting ready for Nov 7th.
price will be above 2 before report....could jump to that next week, and then trend sideways for 2-3 weeks.
I am long, not short. But I am doing some level setting here. Still feel a 100% gain from today in 8-10 months is a great trade in AVXL. People here feel we are looking at 1000% gain in 1 year from now. That is not realistic.
pumping the stock is fine, but c'mon talk about 30-40 billion market cap in 2016 ?? without even phase 3 complete ??? who is on the pipe now.
yes 6-7 after 2b. That is correct. If 2b is going well they will definitely dilute in 2016, to raise cash for ph 3 preparation. So this is pump up market cap without price. Also don't forget warrants that will be sold when 2A bump happens to around $2.75.
As for epilepsy, parkinsons etc. those are just preclinical and phase 1. So not much value right now. And they don't have funds to proceed with moving these further. Their focus is going to be AD only.
Of course, if a big pharma comes in and funds them for eplipsy/pk, that is a different story.
Guys lets be realistic. This talk about $10-15 in 2015 is not going to happen.
I also expect dilution sometime 2016 for them to prepare for Phase 3 trials.
So my prediction -
Early Nov before conference - over $2.
After 2A results - $2.75 - $3.
Dilution in 2016.
Price in 2016 before 2B - $4.
Price in 2016 after 3B - $6-7.
At $7 we are already at $1Billion market cap.
is about $400M market cap at $3. Remember we still have to do Ph 2B.
$3 is still almost a double from here. If you want AXON type valuation, AVXL needs to show strong 2B too. And remember those warrants.
So I see market cap about 1Billion by late of 2016. A double after 2A. Stock price may not double due to warrants, but still big move.
This talk about $10-$15 in 2015 is not real.